Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
13.2M
Short interest
settlement 2026-10-15
9.9
Days to cover
+0.8 days vs prior
60.6%
Short share of volume
2026-11-02
66
Fails to deliver
settlement 2026-09-21
Thu 5 Nov
Next earnings
estimated date
-$3.8M
Insider flow, 90 days
0 buys, 11 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in AMLX is 13,249,442 shares, down 263,311 shares over the last month. Over the last 48 readings it ranged from 1,289,340 shares (31 October 2024) to 14,957,523 shares (29 May 2026). At the reported average volume of 1.3M shares a day that is 9.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/amlx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 13,249,442 | +4.6% | 1,333,949 | 9.93 |
| 2026-09-30 | 12,666,971 | -6.3% | 1,382,131 | 9.16 |
| 2026-09-15 | 13,512,753 | +6.1% | 1,563,524 | 8.64 |
| 2026-08-31 | 12,737,201 | -5.1% | 5,379,256 | 2.37 |
| 2026-08-14 | 13,425,106 | +0.2% | 1,881,057 | 7.14 |
| 2026-07-31 | 13,401,722 | +9.3% | 1,959,109 | 6.84 |
| 2026-07-15 | 12,265,993 | -14.7% | 1,332,522 | 9.21 |
| 2026-06-30 | 14,385,180 | +9.6% | 2,038,056 | 7.06 |
| 2026-06-15 | 13,121,697 | -12.3% | 1,616,733 | 8.12 |
| 2026-05-29 | 14,957,523 | +3.0% | 916,139 | 16.33 |
| 2026-05-15 | 14,514,401 | -1.9% | 1,193,178 | 12.16 |
| 2026-04-30 | 14,800,969 | -0.2% | 1,037,735 | 14.26 |
| 2026-04-15 | 14,831,510 | +4.2% | 1,212,978 | 12.23 |
| 2026-03-31 | 14,231,261 | +2.6% | 1,006,491 | 14.14 |
| 2026-03-13 | 13,864,210 | -4.4% | 1,110,465 | 12.49 |
| 2026-02-27 | 14,497,298 | +1.3% | 760,335 | 19.07 |
| 2026-02-13 | 14,310,589 | +4.1% | 820,962 | 17.43 |
| 2026-01-30 | 13,752,736 | +2.4% | 2,088,336 | 6.59 |
| 2026-01-15 | 13,437,426 | -1.5% | 1,744,583 | 7.70 |
| 2025-12-31 | 13,642,380 | +13.0% | 1,816,629 | 7.51 |
| 2025-12-15 | 12,068,995 | +3.8% | 1,107,605 | 10.90 |
| 2025-11-28 | 11,623,612 | -2.4% | 1,399,419 | 8.31 |
| 2025-11-14 | 11,911,669 | +14.0% | 1,591,901 | 7.48 |
| 2025-10-31 | 10,449,446 | +8.7% | 1,525,945 | 6.85 |
| 2025-10-15 | 9,616,175 | -4.5% | 1,918,584 | 5.01 |
| 2025-09-30 | 10,066,534 | +14.7% | 1,976,363 | 5.09 |
| 2025-09-15 | 8,774,952 | +4.3% | 2,262,263 | 3.88 |
| 2025-08-29 | 8,410,918 | +13.2% | 1,545,878 | 5.44 |
| 2025-08-15 | 7,433,417 | +3.4% | 890,116 | 8.35 |
| 2025-07-31 | 7,192,631 | -3.7% | 1,215,070 | 5.92 |
| 2025-07-15 | 7,466,420 | +12.7% | 1,932,538 | 3.86 |
| 2025-06-30 | 6,622,803 | +63.9% | 2,604,055 | 2.54 |
| 2025-06-13 | 4,039,910 | -2.2% | 849,501 | 4.76 |
| 2025-05-30 | 4,131,846 | -16.9% | 1,030,996 | 4.01 |
| 2025-05-15 | 4,972,837 | +18.4% | 1,121,643 | 4.43 |
| 2025-04-30 | 4,198,819 | -2.6% | 825,406 | 5.09 |
| 2025-04-15 | 4,312,023 | +14.2% | 862,179 | 5.00 |
| 2025-03-31 | 3,775,634 | +0.8% | 627,516 | 6.02 |
| 2025-03-14 | 3,747,333 | +2.6% | 1,043,819 | 3.59 |
| 2025-02-28 | 3,652,423 | +8.1% | 554,487 | 6.59 |
| 2025-02-14 | 3,378,306 | +30.4% | 755,647 | 4.47 |
| 2025-01-31 | 2,591,408 | +4.4% | 1,048,173 | 2.47 |
| 2025-01-15 | 2,482,384 | +27.8% | 808,403 | 3.07 |
| 2024-12-31 | 1,942,447 | +24.1% | 731,100 | 2.66 |
| 2024-12-13 | 1,565,509 | +8.1% | 722,151 | 2.17 |
| 2024-11-29 | 1,448,789 | -5.1% | 1,241,670 | 1.17 |
| 2024-11-15 | 1,526,219 | +18.4% | 1,623,747 | 1.00 |
| 2024-10-31 | 1,289,340 | +27.6% | 2,074,048 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of AMLX volume is 60.6%, up 0.3 points over the last five sessions. Over the last 30 readings it ranged from 26.9% (23 October 2026) to 73.5% (30 October 2026). The latest reading is 7.1 points above the 30-session average of 53.5%, on 422K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 256K | 422K | 60.6% | 2,300 |
| 2026-10-30 | 254K | 345K | 73.5% | 581 |
| 2026-10-29 | 214K | 370K | 57.7% | 0 |
| 2026-10-28 | 219K | 575K | 38.1% | 9,234 |
| 2026-10-27 | 298K | 467K | 63.9% | 14,224 |
| 2026-10-26 | 463K | 768K | 60.3% | 17 |
| 2026-10-23 | 150K | 557K | 26.9% | 0 |
| 2026-10-22 | 256K | 547K | 46.8% | 0 |
| 2026-10-21 | 492K | 674K | 73.0% | 0 |
| 2026-10-20 | 320K | 885K | 36.1% | 0 |
| 2026-10-19 | 196K | 562K | 34.9% | 0 |
| 2026-10-16 | 202K | 555K | 36.4% | 5 |
| 2026-10-15 | 189K | 300K | 63.0% | 0 |
| 2026-10-14 | 286K | 392K | 72.9% | 0 |
| 2026-10-13 | 360K | 494K | 72.9% | 0 |
| 2026-10-12 | 281K | 439K | 64.1% | 0 |
| 2026-10-09 | 318K | 558K | 57.0% | 0 |
| 2026-10-08 | 353K | 1.1M | 33.1% | 0 |
| 2026-10-07 | 388K | 613K | 63.4% | 0 |
| 2026-10-06 | 335K | 609K | 55.0% | 0 |
| 2026-10-05 | 169K | 380K | 44.4% | 295 |
| 2026-10-02 | 283K | 386K | 73.4% | 17 |
| 2026-10-01 | 349K | 624K | 55.9% | 5,103 |
| 2026-09-30 | 255K | 440K | 57.9% | 0 |
| 2026-09-29 | 204K | 470K | 43.4% | 0 |
| 2026-09-28 | 162K | 242K | 67.0% | 634 |
| 2026-09-25 | 237K | 486K | 48.8% | 0 |
| 2026-09-24 | 303K | 669K | 45.4% | 418 |
| 2026-09-23 | 258K | 767K | 33.7% | 300 |
| 2026-09-22 | 267K | 591K | 45.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 21 September 2026, the fails-to-deliver balance in AMLX is 66 shares, up 65 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (31 August 2026) to 89,736 shares (24 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-21 | 66 | $32.41 | $2K |
| 2026-08-31 | 1 | $34.74 | $35 |
| 2026-08-26 | 42 | $37.46 | $2K |
| 2026-08-25 | 154 | $38.15 | $6K |
| 2026-08-24 | 1,488 | $38.66 | $58K |
| 2026-08-21 | 6,973 | $39.66 | $277K |
| 2026-08-19 | 63,699 | $35.11 | $2.2M |
| 2026-08-10 | 297 | $22.82 | $7K |
| 2026-07-28 | 21 | $19.49 | $409 |
| 2026-07-24 | 100 | $17.59 | $2K |
| 2026-07-23 | 100 | $17.70 | $2K |
| 2026-07-22 | 100 | $18.50 | $2K |
| 2026-07-14 | 140 | $17.41 | $2K |
| 2026-07-08 | 859 | $18.17 | $16K |
| 2026-06-22 | 13,556 | $15.67 | $212K |
| 2026-06-15 | 186 | $14.59 | $3K |
| 2026-06-04 | 3 | $13.20 | $40 |
| 2026-06-02 | 40 | $14.07 | $563 |
| 2026-06-01 | 13,737 | $14.35 | $197K |
| 2026-05-22 | 13 | $13.93 | $181 |
| 2026-05-19 | 36 | $12.86 | $463 |
| 2026-05-18 | 8,340 | $13.29 | $111K |
| 2026-05-13 | 16,807 | $14.44 | $243K |
| 2026-04-30 | 347 | $15.60 | $5K |
| 2026-04-14 | 173 | $16.47 | $3K |
| 2026-04-06 | 8 | $14.95 | $120 |
| 2026-03-24 | 89,736 | $13.53 | $1.2M |
| 2026-03-17 | 23 | $14.38 | $331 |
| 2026-03-13 | 683 | $14.38 | $10K |
| 2026-03-05 | 4,372 | $15.05 | $66K |
Insider trades
SEC Form 4, newest first. JSONInsiders at AMLX reported 11 open-market sells worth $3.8M in the last 90 days and no open-market buys. Latest filing: MILNE GEORGE M JR (Director) on 2026-10-05.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | MILNE GEORGE M JR | Director | Sell | 30K | $27.70 | $831K | 783K |
| 2026-09-10 | Bedrosian Camille L | Chief Medical Officer | Sell | 2K | $33.09 | $69K | 278K |
| 2026-09-10 | Bedrosian Camille L | Chief Medical Officer | Sell | 8K | $32.21 | $256K | 280K |
| 2026-09-10 | FRATES JAMES M | Chief Financial Officer | Sell | 1K | $33.23 | $35K | 234K |
| 2026-09-10 | FRATES JAMES M | Chief Financial Officer | Sell | 10K | $32.27 | $315K | 235K |
| 2026-09-10 | Mazzariello Gina | Chief Legal Officer | Sell | 11 | $33.34 | $367 | 191K |
| 2026-09-10 | Mazzariello Gina | Chief Legal Officer | Sell | 10K | $32.46 | $309K | 191K |
| 2026-09-10 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 919 | $33.15 | $30K | 3.6M |
| 2026-09-10 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 30K | $32.16 | $950K | 3.6M |
| 2026-09-10 | Klee Justin B. | Co-Chief Executive Officer | Sell | 1K | $33.16 | $48K | 3.6M |
| 2026-09-10 | Klee Justin B. | Co-Chief Executive Officer | Sell | 29K | $32.13 | $933K | 3.6M |
| 2026-08-31 | Firestone Karen | Director | Exercise or conversion | 25K | $5.05 | $126K | 117K |
| 2026-08-31 | Firestone Karen | Director | Exercise or conversion | 25K | $1.76 | $44K | 92K |
| 2026-08-18 | FRATES JAMES M | Chief Financial Officer | Grant | 23K | $0.00 | $0 | 244K |
| 2026-08-18 | Klee Justin B. | Co-Chief Executive Officer | Grant | 60K | $0.00 | $0 | 3.6M |
| 2026-08-18 | Mazzariello Gina | Chief Legal Officer | Grant | 21K | $0.00 | $0 | 200K |
| 2026-08-18 | Bedrosian Camille L | Chief Medical Officer | Grant | 23K | $0.00 | $0 | 288K |
| 2026-08-18 | Cohen Joshua B | Co-Chief Executive Officer | Grant | 60K | $0.00 | $0 | 3.6M |
| 2026-07-10 | Mazzariello Gina | Chief Legal Officer | Sell | 15K | $17.61 | $264K | 179K |
| 2026-07-09 | Mazzariello Gina | Chief Legal Officer | Sell | 15K | $18.32 | $275K | 194K |
| 2026-05-21 | Firestone Karen | Director | Buy | 4K | $13.51 | $51K | 67K |
| 2026-03-05 | Cohen Joshua B | Co-Chief Executive Officer | Grant | 249K | $0.00 | $0 | 3.6M |
| 2026-03-05 | Mazzariello Gina | Chief Legal Officer | Grant | 75K | $0.00 | $0 | 209K |
| 2026-03-05 | FRATES JAMES M | Chief Financial Officer | Grant | 96K | $0.00 | $0 | 262K |
| 2026-03-05 | Klee Justin B. | Co-Chief Executive Officer | Grant | 249K | $0.00 | $0 | 3.6M |
| 2026-03-05 | Bedrosian Camille L | Chief Medical Officer | Grant | 96K | $0.00 | $0 | 265K |
| 2026-03-02 | Klee Justin B. | Co-Chief Executive Officer | Sell | 29K | $14.47 | $424K | 3.3M |
| 2026-03-02 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 29K | $14.48 | $424K | 3.3M |
| 2026-03-02 | Bedrosian Camille L | Chief Medical Officer | Sell | 6K | $14.58 | $94K | 169K |
| 2026-03-02 | FRATES JAMES M | Chief Financial Officer | Sell | 8K | $14.52 | $115K | 166K |
| 2026-03-02 | Mazzariello Gina | Chief Legal Officer | Sell | 7K | $14.52 | $99K | 134K |
| 2026-02-23 | Mazzariello Gina | Chief Legal Officer | Sell | 3K | $14.14 | $48K | 141K |
| 2026-02-02 | FRATES JAMES M | Chief Financial Officer | Sell | 4K | $14.65 | $52K | 174K |
| 2026-02-02 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 16K | $14.68 | $228K | 3.4M |
| 2026-02-02 | Mazzariello Gina | Chief Legal Officer | Sell | 3K | $14.65 | $51K | 145K |
| 2026-02-02 | Klee Justin B. | Co-Chief Executive Officer | Sell | 16K | $14.69 | $228K | 3.4M |
| 2026-01-16 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 2K | $13.83 | $27K | 3.4M |
| 2026-01-16 | Cohen Joshua B | Co-Chief Executive Officer | Exercise or conversion | 3K | $7.57 | $21K | 3.4M |
| 2026-01-16 | Klee Justin B. | Co-Chief Executive Officer | Sell | 2K | $13.89 | $28K | 3.4M |
| 2026-01-16 | Klee Justin B. | Co-Chief Executive Officer | Exercise or conversion | 3K | $7.57 | $22K | 3.4M |
| 2026-01-15 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 136K | $13.59 | $1.9M | 3.4M |
| 2026-01-15 | Cohen Joshua B | Co-Chief Executive Officer | Exercise or conversion | 197K | $7.57 | $1.5M | 3.5M |
| 2026-01-15 | Klee Justin B. | Co-Chief Executive Officer | Sell | 136K | $13.58 | $1.8M | 3.4M |
| 2026-01-15 | Klee Justin B. | Co-Chief Executive Officer | Exercise or conversion | 197K | $7.57 | $1.5M | 3.5M |
| 2026-01-12 | MILNE GEORGE M JR | Director | Gift | 18K | $0.00 | $0 | 813K |
| 2026-01-06 | FRATES JAMES M | Chief Financial Officer | Sell | 3K | $11.11 | $37K | 177K |
| 2026-01-06 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 8K | $11.09 | $86K | 3.3M |
| 2026-01-06 | Klee Justin B. | Co-Chief Executive Officer | Sell | 8K | $11.09 | $86K | 3.3M |
| 2025-12-23 | Firestone Karen | Director | Buy | 8K | $12.45 | $101K | 63K |
| 2025-12-01 | Bedrosian Camille L | Chief Medical Officer | Sell | 7K | $14.35 | $94K | 176K |
| 2025-09-30 | Klee Justin B. | Co-Chief Executive Officer | Sell | 200 | $15.01 | $3K | 3.3M |
| 2025-09-30 | Klee Justin B. | Co-Chief Executive Officer | Sell | 30K | $14.37 | $428K | 3.3M |
| 2025-09-30 | Mazzariello Gina | Chief Legal Officer | Sell | 9K | $14.58 | $129K | 148K |
| 2025-09-30 | FRATES JAMES M | Chief Financial Officer | Sell | 11K | $14.65 | $155K | 280K |
| 2025-09-30 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 200 | $15.00 | $3K | 3.3M |
| 2025-09-30 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 30K | $14.34 | $426K | 3.3M |
| 2025-09-30 | Bedrosian Camille L | Chief Medical Officer | Sell | 12K | $14.58 | $176K | 182K |
| 2025-08-13 | Mazzariello Gina | Chief Legal Officer | Sell | 15K | $8.34 | $125K | 157K |
| 2025-08-12 | Mazzariello Gina | Chief Legal Officer | Sell | 15K | $8.07 | $121K | 172K |
| 2025-05-22 | Mazzariello Gina | Chief Legal Officer | Gift | 1K | $0.00 | $0 | 187K |
| 2025-03-31 | Klee Justin B. | Co-Chief Executive Officer | Sell | 21K | $3.46 | $74K | 3.4M |
| 2025-03-31 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 21K | $3.47 | $75K | 3.4M |
| 2025-03-31 | Mazzariello Gina | Chief Legal Officer | Sell | 9K | $3.48 | $32K | 188K |
| 2025-03-31 | Bedrosian Camille L | Chief Medical Officer | Sell | 12K | $3.47 | $43K | 194K |
| 2025-03-31 | FRATES JAMES M | Chief Financial Officer | Sell | 11K | $3.47 | $38K | 291K |
| 2025-03-20 | Zeiher Bernhardt G | Director | Buy | 10K | $3.70 | $37K | 10K |
| 2025-03-06 | FRATES JAMES M | Chief Financial Officer | Grant | 68K | $0.00 | $0 | 302K |
| 2025-03-06 | Cohen Joshua B | Co-Chief Executive Officer | Grant | 180K | $0.00 | $0 | 3.4M |
| 2025-03-06 | Klee Justin B. | Co-Chief Executive Officer | Grant | 180K | $0.00 | $0 | 3.4M |
| 2025-03-06 | Bedrosian Camille L | Chief Medical Officer | Grant | 68K | $0.00 | $0 | 207K |
| 2025-03-06 | Mazzariello Gina | Chief Legal Officer | Grant | 64K | $0.00 | $0 | 197K |
| 2025-03-03 | Mazzariello Gina | Chief Legal Officer | Sell | 2K | $3.12 | $5K | 133K |
| 2025-03-03 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 5K | $3.17 | $15K | 3.2M |
| 2025-03-03 | Klee Justin B. | Co-Chief Executive Officer | Sell | 5K | $3.15 | $14K | 3.2M |
| 2025-02-24 | Mazzariello Gina | Chief Legal Officer | Sell | 4K | $3.15 | $13K | 135K |
| 2025-02-05 | Klee Justin B. | Co-Chief Executive Officer | Exercise or conversion | 36K | $1.57 | $57K | 3.2M |
| 2025-02-03 | Klee Justin B. | Co-Chief Executive Officer | Sell | 12K | $3.47 | $41K | 3.2M |
| 2025-02-03 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 12K | $3.47 | $41K | 3.2M |
| 2025-02-03 | Mazzariello Gina | Chief Legal Officer | Sell | 4K | $3.49 | $13K | 139K |
| 2025-01-24 | MILNE GEORGE M JR | Director | Gift | 28K | $0.00 | $0 | 831K |
| 2025-01-06 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 7K | $4.05 | $30K | 3.2M |
| 2025-01-06 | Klee Justin B. | Co-Chief Executive Officer | Sell | 7K | $4.04 | $30K | 3.2M |
| 2024-12-02 | Bedrosian Camille L | Chief Medical Officer | Sell | 5K | $5.54 | $30K | 138K |
| 2024-11-04 | Klee Justin B. | Co-Chief Executive Officer | Exercise or conversion | 64K | $1.57 | $100K | 3.2M |
| 2024-09-30 | Mazzariello Gina | Chief Legal Officer | Sell | 9K | $3.20 | $28K | 143K |
| 2024-09-30 | Bedrosian Camille L | Chief Medical Officer | Sell | 11K | $3.20 | $37K | 144K |
| 2024-09-30 | Cohen Joshua B | Co-Chief Executive Officer | Sell | 19K | $3.20 | $59K | 3.2M |
| 2024-09-30 | Klee Justin B. | Co-Chief Executive Officer | Sell | 19K | $3.20 | $59K | 3.1M |
| 2024-09-23 | Cohen Joshua B | Co-Chief Executive Officer | Exercise or conversion | 2K | $1.57 | $3K | 3.2M |
| 2024-09-12 | FRATES JAMES M | Chief Financial Officer | Buy | 40K | $2.53 | $101K | 233K |
| 2024-09-12 | Cohen Joshua B | Co-Chief Executive Officer | Exercise or conversion | 34K | $1.57 | $54K | 3.2M |
| 2024-09-05 | Firestone Karen | Director | Buy | 50K | $2.13 | $107K | 55K |
| 2024-09-03 | MILNE GEORGE M JR | Director | Buy | 100K | $2.20 | $220K | 859K |
| 2024-05-15 | Mazzariello Gina | Chief Legal Officer | Sell | 10K | $1.88 | $20K | 151K |
| 2024-05-15 | Quimi Daphne | Director | Buy | 2K | $1.89 | $4K | 5K |
| 2024-05-14 | Quimi Daphne | Director | Buy | 3K | $1.89 | $5K | 3K |
| 2024-04-16 | Bedrosian Camille L | Chief Medical Officer | Grant | 97K | $0.00 | $0 | 155K |
| 2024-04-16 | Klee Justin B. | Co-Chief Executive Officer | Grant | 180K | $0.00 | $0 | 3.1M |
| 2024-04-16 | Mazzariello Gina | Chief Legal Officer | Grant | 81K | $0.00 | $0 | 162K |
| 2024-04-16 | Cohen Joshua B | Co-Chief Executive Officer | Grant | 180K | $0.00 | $0 | 3.2M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON25 Form 144 notices on file for AMLX worth $12.2M at the prices reported; 6 in the last 90 days worth $5.7M. Latest: GEORGE MILNE filed on 2026-10-05 to sell 100,000 shares ($2.8M) from 2026-10-05.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-05 | GEORGE MILNEDirector | 100K | $2.8M | 0.090% | 2026-10-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-11 | Klee Justin B.Officer, Director | 30K | $980K | 0.843% | 2026-09-10 | Morgan Stanley Smith Barney LLC |
| 2026-09-11 | Frates James MOfficer | 11K | $350K | 4.627% | 2026-09-10 | Morgan Stanley Smith Barney LLC |
| 2026-09-11 | Bedrosian Camille LOfficer | 10K | $325K | 3.606% | 2026-09-10 | Morgan Stanley Smith Barney LLC |
| 2026-09-11 | Mazzariello GinaOfficer | 10K | $310K | 4.997% | 2026-09-10 | Morgan Stanley Smith Barney LLC |
| 2026-09-11 | Cohen Joshua BOfficer, Director | 30K | $981K | 0.843% | 2026-09-10 | Morgan Stanley Smith Barney LLC |
| 2026-07-09 | GINA MAZZARIELLOOfficer | 30K | $536K | 0.027% | 2026-07-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | Mazzariello GinaOfficer | 7K | $99K | 5.091% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Cohen Joshua BOfficer, Director | 29K | $424K | 0.878% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Klee Justin B.Officer, Director | 29K | $424K | 0.878% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Bedrosian Camille LOfficer | 6K | $94K | 3.816% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Frates James MOfficer | 8K | $115K | 4.775% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-23 | Mazzariello GinaOfficer | 3K | $48K | 2.420% | 2026-02-23 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Cohen Joshua BOfficer, Director | 16K | $228K | 0.461% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Klee Justin B.Officer, Director | 16K | $228K | 0.461% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Mazzariello GinaOfficer | 3K | $51K | 2.383% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Frates James MOfficer | 4K | $52K | 2.050% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-01-16 | JUSTIN KLEEDirector, Officer | 2K | $27K | 0.002% | 2026-01-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-16 | JOSHUA COHENDirector, Officer | 2K | $27K | 0.002% | 2026-01-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-15 | JOSHUA COHENDirector, Officer | 136K | $1.9M | 0.124% | 2026-01-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-15 | JUSTIN KLEEDirector, Officer | 136K | $1.9M | 0.124% | 2026-01-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-06 | Frates James MOfficer | 3K | $37K | 1.200% | 2026-01-06 | Morgan Stanley Smith Barney LLC |
| 2026-01-06 | Klee Justin B.Officer, Director | 8K | $86K | 0.233% | 2026-01-06 | Morgan Stanley Smith Barney LLC |
| 2026-01-06 | Cohen Joshua BOfficer, Director | 8K | $86K | 0.233% | 2026-01-06 | Morgan Stanley Smith Barney LLC |
| 2025-12-01 | Bedrosian Camille LOfficer | 7K | $94K | 3.457% | 2025-12-01 | Morgan Stanley Smith Barney LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of AMLX in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (16,468,419 shares), filed 2026-02-05 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-15 | 13G/Ano. 4 | Joseph Edelmanindividual | 8.3M | 7.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Perceptive Advisors LLCinvestment adviser | 8.3M | 7.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Perceptive Life Sciences Master Fund, Ltd.corporation | 8.3M | 7.5% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 1 | TCG Crossover GP II, LLCother entity | 6.2M | 5.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | TCG Crossover Fund II, L.P.partnership | 6.2M | 5.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Chen Yuindividual | 6.2M | 5.7% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | Adage Capital Management, L.P.investment adviser, partnership | 2.8M | 2.5% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | Robert Atchinsonparent holding company, individual | 2.8M | 2.5% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | Phillip Grossparent holding company, individual | 2.8M | 2.5% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 1 | FMR LLCparent holding company | 16.5M | 15.0% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 16.5M | 15.0% | 2025-12-31 |
| 2026-01-21 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 7.8M | 7.1% | 2025-12-31 |
| 2025-11-17 | 13G | Commodore Capital Master LPpartnership | 5.7M | 5.1% | 2025-11-10 |
| 2025-11-17 | 13G | Commodore Capital LPinvestment adviser, partnership | 5.7M | 5.1% | 2025-11-10 |
| 2025-11-17 | 13G | Robert Egen Atkinsonparent holding company, individual | 5.7M | 5.1% | 2025-11-10 |
| 2025-11-17 | 13G | Michael Kramarzparent holding company, individual | 5.7M | 5.1% | 2025-11-10 |
| 2025-11-14 | 13G/Ano. 1 | Point72 Asset Management, L.P.partnership | 2.8M | 2.6% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Point72 Capital Advisors, Inc.corporation | 2.8M | 2.6% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Steven A. Cohenindividual | 2.8M | 2.6% | 2025-09-30 |
13F holders
Tracked managers holding AMLX at their latest 13F. JSON4 of the 30 tracked managers held AMLX at their latest 13F, $17.4M in total at quarter-end prices. Two Sigma Investments is the largest at $10.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 593K | $10.7M | 0.01% | +431K |
| Citadel Advisors | 2026-06-30 | 179K | $3.2M | 0.00% | -233K |
| D. E. Shaw & Co. | 2026-06-30 | 174K | $3.1M | 0.00% | +100K |
| AQR Capital Management | 2026-06-30 | 21K | $374K | 0.00% | -8K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Amylyx Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Amylyx Pharmaceuticals (AMLX), SEC CIK 1658551, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-21.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-05.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-05.JSON and CSV
- Company record
- EDGAR filing index for CIK 1658551Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of AMLX is sold short?
13,249,442 shares were held short at the 2026-10-15 settlement, 9.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is AMLX's daily short volume?
On 2026-11-02, 255,633 of the 421,702 AMLX shares reported to FINRA were sold short, 60.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does AMLX have fails to deliver?
The SEC's latest file shows 66 AMLX shares failed to deliver at settlement 2026-09-21. Fails are reported per settlement date and published twice a month with a lag.
Are AMLX insiders buying or selling?
Insiders at AMLX reported 11 open-market sells worth $3.8M in the last 90 days and no open-market buys. Latest filing: MILNE GEORGE M JR (Director) on 2026-10-05.
Have AMLX insiders filed to sell?
25 Form 144 notices on file for AMLX worth $12.2M at the prices reported; 6 in the last 90 days worth $5.7M. Latest: GEORGE MILNE filed on 2026-10-05 to sell 100,000 shares ($2.8M) from 2026-10-05.
Who owns 5% or more of AMLX?
13 holders report 5% or more of AMLX in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (16,468,419 shares), filed 2026-02-05 for an event on 2025-12-31.
Which tracked 13F managers own AMLX?
4 of the 30 tracked 13F managers held AMLX shares at their latest filing, $17.4M in all. The largest: Two Sigma Investments (593K shares, $10.7M), Ken Griffin's Citadel Advisors (179K shares, $3.2M), D. E. Shaw & Co. (174K shares, $3.1M), Cliff Asness's AQR Capital Management (21K shares, $374K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.